SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed on August 5, 2019, by BioSig Technologies, Inc. (the "Company"), a Delaware corporation. The report details a material definitive agreement entered into by the Company and its wholly-owned subsidiary, NeuroClear Technologies, Inc. ("NeuroClear").
Key Financial Metrics and Transaction Details
The filing discloses a private placement transaction rather than standard periodic financial results. Key metrics include:
- Transaction Type: NeuroClear Private Placement of common stock.
- Shares Issued: 524,000 shares of NeuroClear common stock.
- Price Per Share: $5.00.
- Total Proceeds: $2,620,000.
- Expected Closing Date: On or before August 9, 2019 (subject to a potential 60-day extension).
- Investor Base: Certain accredited investors.
The filing text does not provide clear values for the Company's overall revenue, profit, cash flow, margins, debt, or liquidity positions as this is a current report focused on a specific event.
Material Changes and Share Exchange Provisions
A material feature of the agreement is a contingent share exchange provision. If NeuroClear's common stock is not listed on a national securities exchange by October 31, 2020, or if a change of control occurs (whichever is earlier), investors may elect to exchange each share of NeuroClear common stock for 0.9 shares of BioSig Technologies, Inc. common stock.
Guidance, Risks, and Contingencies
Regulatory Status: The offering is unregistered, relying on exemptions under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933.
Contingencies: Closing is subject to customary conditions. The closing date may be extended by NeuroClear without notice for up to 60 days.
Risks: The transaction creates a potential future dilution event for BioSig Technologies, Inc. shareholders if the share exchange provision is triggered due to a failure to list NeuroClear stock or a change of control.
Key Facts for Investor Verification
- Verify the actual closing date of the $2.62 million private placement.
- Monitor NeuroClear's progress toward listing its common stock on a national securities exchange by the October 31, 2020 deadline.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific representations, warranties, and termination rights.
- Assess the potential dilution impact on BioSig Technologies, Inc. if the 0.9-to-1 share exchange ratio is exercised by investors.